TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04269889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag will be administered to participants 12 years of age an above will receive the adult dose of 150 mg by mouth daily. Participants between ages of 6 and 11 years old will start at 75 mg by mouth daily, and children 2 and 5 years of age will start at 2.5 mg/kg, not to exceed 75 mg by mouth daily.~To adjust for the higher expected exposure in participants of East Asian and South East Asian ancestry, the starting dose for East Asian and South East Asian participants 12 years of age and above will be 75 mg by mouth once daily. For East Asian and South East Asian participants between 6 and 11 years of age, the starting dose will be 37.5 mg once daily by mouth, and for children between 2 and 5, the starting dose will be 1.25 mg/kg by mouth.
Study: NCT05266261

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibandronate Oral Tablet
Description: 150 mg of ibandronate + 24,000 IU of cholecalciferol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate Oral Tablet
Description: 150 mg of ibandronate + 24,000 IU of cholecalciferol
Study: NCT02887651

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Cavity boost radiation
Description: Cavity boost radiation therapy with 10 x 3 Gy for patients suffering from complete resected cerebral metastases
Study: NCT01149135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue enriched light with a low intensity
Description: 30 minutes in the morning, 750 lux

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard light treatment
Description: standard light treatment, 30 minutes, 10 000 lux
Study: NCT02783950

Intervention type: OTHER
Group type: OTHER
Intervention: Decipher Prostate Cancer Classifier
Description: The Decipher test (GenomeDx Biosciences, San Diego, CA) is a genomic test that predicts high grade disease, the probability of metastasis and prostate cancer-specific mortality for men with prostate cancer.
Study: NCT02939183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate Release (IR) Formulation
Description: Immediate Release (IR) Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate Release (IR) Formulation
Description: Immediate Release (IR) Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gastro-Retentive (GR) Formulation
Description: Gastro-Retentive (GR) Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gastro-Retentive (GR) Formulation
Description: Gastro-Retentive (GR) Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gastro-Retentive (GR) Formulation
Description: Gastro-Retentive (GR) Formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide
Study: NCT01397201

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Fluticasone propionate
Study: NCT04691401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence System (CAD EYE, Fujifilm Co.)
Description: A dedicated CNN-based AI system (CAD EYE, Fujifilm Co, Tokyo, Japan) has been recently developed. The Computer-aided diagnosis (CAD) CAD EYE system is a real-time computer-assisted image analysis that allows automatic polyp identification without modifications to the colonoscope or to the actual endoscopic procedure. When CAD EYE identifies a polyp, both a visual (a green blinking box surrounding the identified polyp, called the detection box) and an acoustic alarm pop up and attract the endoscopist attention. Around the endoscopic image a visual assist circle is shown and lights up in the direction where the suspicious polyp is detected.
Study: NCT04908657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil 20 MG
Description: oral sildenafil 20 mg three times per day for 3 years
Study: NCT02583373

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAL02 Low-dose
Description: Two doses of CAL02 (low-dose) administered 2 times (24 hours apart) as i.v. infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAL02 High-dose
Description: Two doses of CAL02 (high-dose) administered 2 times (24 hours apart) as i.v. infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered administered 2 times (24 hours apart) as i.v. infusion
Study: NCT00792077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 5 mg daily for 56 days.
Study: NCT03838965

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biobeat sensor
Description: biobeat sensor is a noninvasive sensor of the the hymodynamic measures during the childbirth and after 24 hours.
Study: NCT00122278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 10mg IV
Study: NCT02783326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Pulmonary rehabilitation, exercise in COPD individuals and health individuals

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Pulmonary rehabilitation, exercise in COPD individuals and health individuals
Study: NCT02260258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Neuromuscular Blockade

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline
Study: NCT02725411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Orally administered Celecoxib 100 mg twice daily for 56 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg
Description: Subcutaneous injection of tanezumab 5 mg every 8 weeks for 56 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tanezumab 10 mg
Description: Subcutaneous injection of tanezumab 10 mg every 8 weeks for 56 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for celecoxib
Description: Orally administered the placebo twice daily for 56 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for celecoxib
Description: Orally administered the placebo twice daily for 56 weeks
Study: NCT00122278

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Dexamethasone 10mg IV
Study: NCT02002611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobeglitazone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Study: NCT05932784

Intervention type: DEVICE
Intervention: transesophageal echocardiography
Description: Utilizing transesophageal echocardiography (TEE) during resuscitation allows medical professionals to determine if a patient's aortic valve is being compressed while receiving chest compressions, providing valuable insight to optimize the resuscitation process.
Study: NCT03858478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy arm
Description: BIKTARVY : one tablet QD, every day between D0 and M12 includind - TAF (25mg) / FTC (200mg) / BICTEGRAVIR (50mg)
Study: NCT00315159

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Sentinel Node Biopsy
Description: Inguinal sentinel node biopsy will be performed.
Study: NCT01128751

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embol-X intra-aortic emboli filter
Description: Patients in this arm receive intra-aortic filter designed to catch solid debris for neuroprotection during surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DBT dynamic bubble trap
Description: Patients in this arm receive a dynamic bubble trap to reduce gaseous micro-emboli from cardiopulmonary bypass for neuroprotection during surgery

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Control group
Description: In comparison to arm 1 and 2, patients in this arm do not receive an additional intervention during surgery
Study: NCT04620395

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Punch biopsy
Description: A standardized biopsy kit is used for a synovial fluid tap and subsequent acquisition of up to 7 Punch biopsies through an introducer (part of the kit)
Study: NCT01039974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK962040
Description: GSK962040. Planned doses per cohort as follows:~Cohort 1 planned dose = 10 mg; Cohort 2 to be determined based on data from Cohort 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: 400 mg
Study: NCT01050127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-436
Description: See Arm Description for details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-436
Description: See Arm Description for details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-436
Description: See Arm Description for details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See Arm Description for details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See Arm Description for details.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See Arm Description for details.
Study: NCT04396496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab Injection
Description: DARA is a human monoclonal antibody that specifically recognizes the CD38 molecule that is expressed at a high level in a variety of hematological malignancies, including myeloma cells.~DARA injection will be given with oral lenalidomide for up to 12 four week cycles.
Study: NCT01297998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine , cisplatin
Description: Dose of gemcitabine and cisplatin and treatment schedule
Study: NCT02493582

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-Induced Killer Cells
Description: CIKs are used with Apatinib to treat lung adenocarcinoma patients with wild-type EGFR

Intervention type: DRUG
Group type: OTHER
Intervention: Apatinib
Description: Advanced lung adenocarcinoma patients with wild-type EGFR take Apatinib 850mg qd by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Advanced lung adenocarcinoma patients with wild-type EGFR take Apatinib 850mg qd by mouth.
Study: NCT03632343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Squad+ with Nurse Support
Description: Pain Squad+ smartphone app with algorithm-driven pain management advice registered nurse (RN)-initiated pain support. Email alerts related to clinically important incoming pain reports (3 consecutive reports of pain \>3/10) will be sent to the study RN who will contact the healthcare team at the participants' home center to initiate clinician-driven intervention, which may be outside of the scope of the self-management algorithm. The RN will contact the participant within 12 hours of receiving the alert, including on weekends.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Squad+
Description: Pain Squad+ smartphone app with algorithm-driven pain management advice without RN-initiated pain support.
Study: NCT00752024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YL-1 type of intracranial hematoma puncture needle
Description: YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe.~To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dehydrating agent, haemostatic
Description: In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
Study: NCT02616419

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy® device
Description: Just before the needle-related procedure, the Buzzy®, combining an ice pack and vibration integrated to a plastic bee, will be applied 5 cm above the needle insertion site and will be maintained in place throughout the painful procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maxilene® (Lidocaine liposomal 4%)
Description: Maxilene® topical anaesthetic cream will be applied 30 minutes before the needle-related procedure at the insertion site.
Study: NCT03589014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Patients randomized to the experimental arm will receive propranolol on top of standard recommended treatment for CCM. Initial oral dose of 40 mg bid will be uptitrated to 80 mg bid in the absence of excessive bradycardia or hypotension. Doses as low as 10 mg bid and up to 160 mg bid, 20 to 320mg daily, are acceptable according to tolerability.
Study: NCT00356733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin administration
Description: 50 IU/kg/week EPO to a target haemoglobin level of 13.7 g/dL for men and 13.4 g/dL for women (group A) or to a target comparable to starting hemoglobin level (group B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin administration
Description: 50 IU/kg/week EPO to a target haemoglobin level of 13.7 g/dL for men and 13.4 g/dL for women (group A) or to a target comparable to starting hemoglobin level (group B)
Study: NCT03718871

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV testing at traditional healer practices
Description: HIV 1/2 antigen-antibody POC test (Oraquick©) will be administered to those participants who agree to test. Pre-test counseling will be performed before results are delivered. Clients with positive tests will be provided with detailed contact information for the MUST ISS clinic, and given specific instructions to present to the clinic as soon as possible for confirmatory testing and linkage to care.
Study: NCT03298776

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-Scan
Description: I-Scan is a digital enhancement technique. These endoscopes already have greater definition compared to many standard endoscopes but they also utilise a 'zoom' function and digital image enhancement.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard endoscopy
Description: Patients referred for standard endoscopy to receive standard of care only
Study: NCT01670318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: platinum chromium everolimus-eluting stent (PROMUS Element by Boston Scientific, Massachusetts)
Study: NCT04163497

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICU Diaries
Description: To explore the effects of providing an ICU Diary in the symptoms of anxiety, depression and PTSD within patients who were hospitalized in the unit.
Study: NCT04036734

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Longitudinal
Description: Longitudinal orientation of ultrasound to long axis of vein to guide access needle

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Transverse
Description: Transverse orientation of ultrasound to long axis of vein to guide access needle
Study: NCT01193660

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Infusion
Description: The subjects will be undertaken allogeneic umbilical cord blood infusion (total nucleated cells \> 3x10\^7/kg) intravenously under non-myeloablative immunosuppression (maintaining blood level of cyclosporine as 100-200ng/mL for 1 month).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoietin Injection
Description: Erythropoietin will be given as the schedule of twice a week for 4 weeks with the dosage of 500 IU/kg for 2 times intravenously and 250 IU/kg subcutaneously for 6 times.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin Injection
Description: Erythropoietin will be given as the schedule of twice a week for 4 weeks with the dosage of 500 IU/kg for 2 times intravenously and 250 IU/kg subcutaneously for 6 times.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Rehabilitation
Description: All subjects should participate in active rehabilitation. They received two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 5 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Active Rehabilitation
Description: All subjects should participate in active rehabilitation. They received two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 5 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Rehabilitation
Description: All subjects should participate in active rehabilitation. They received two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 5 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Umbilical Cord Blood
Description: Placebo Umbilical Cord Blood will be given except the Experimental arm. Placebo Umbilical Cord Blood was made using peripheral blood. Participants and Investigators maintained as blind.
Study: NCT04058392

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Camu Camu Capsules
Description: Camu Camu powder encapsulated (500mg each). 2 capsules per day will be used for this study
Study: NCT01193660

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Umbilical Cord Blood
Description: Placebo Umbilical Cord Blood will be given except the Experimental arm. Placebo Umbilical Cord Blood was made using peripheral blood. Participants and Investigators maintained as blind.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Erythropoietin
Description: Placebo Erythropoietin containing Normal Saline
Study: NCT00372203

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endobronchial Ultrasound Guided Transthoracic Needle Biopsy
Description: Endobronchial Ultrasound Guided Transthoracic Needle Biopsy of mediastinal lymph nodes at the time of the mediastinoscopy.
Study: NCT01279473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Study: NCT02503007

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB-FA
Study: NCT03920410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: serotonergic stimulation
Description: Increase of serotonergic activity by a single oral administration of 10 mg Escitalopram, a Selective Serotonin Reuptake Inhibitor (SSRI), packed in a coloured hydroxypropylmethylcellulose capsule.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no serotonergic stimulation
Description: Oral administration of a placebo. The placebo will consist of a coloured hydroxypropylmethylcellulose capsule filled with microcrystalline cellulose.
Study: NCT01854203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inductive chemotherapy + concurrent cisplatin and IMRT
Description: Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2，on day 1) repeated every week for 6 cycles during radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inductive chemotherapy + IMRT
Description: Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT.
Study: NCT04953429

Intervention type: BEHAVIORAL
Intervention: workload
Description: Mental needs, physical needs, time needs, self performance, effort, frustration, technical autonomy, decision-making autonomy and work needs of nursing work
Study: NCT02725411

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for tanezumab
Description: Subcutaneous injection of the placebo every 8 weeks for 56 weeks
Study: NCT01504711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosaprepitant dimeglumine
Description: Given IV
Study: NCT04132505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Given PO
Study: NCT03969329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Etelcalcetide has been shown to be safe and efficacious in treating adult chronic kidney disease (CKD) patients with secondary hyperparathyroidism (SHPT) by simultaneously controlling intact parathyroid hormone (iPTH), calcium (Ca), and phosphorus and has recently been approved for use in adult patients with secondary hyperparathyroidism (SHPT) treated with hemodialysis in both the United States and Europe
Study: NCT04398459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Each recruited subject will accept Ibrutinib treatment.
Study: NCT06673927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-1139
Description: Single oral dose, 2mg, 5mg, 10mg, 20mg, 40mg, 60mg, 80mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YZJ-1139
Description: Multiple Dosing ，Each oral dose of 10 mg，20 mg，40 mg or 60 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administration
Study: NCT02547948

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-targeting CAR T Cells infusion
Description: CD19-targeting 2nd generation CAR t cells infusion for refractory B cell lymphoma
Study: NCT02428608

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DWP-450 (Botulinum purified neurotoxin, Type A)
Description: Botulinum toxin, Type A
Study: NCT00949273

Intervention type: PROCEDURE
Intervention: cylindrical abdominoperineal resection
Description: Extended abdominoperineal resection with human acellular dermal matrix reconstruction of the pelvic floor for rectal cancer